Communiqués Jasper Therapeutics, Inc.

Actions

JSPR

US4718712023

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
0,6603 ^USD	-5,77 %		-6,82 %	-63,92 %

14/08	Jasper Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
12/08	Jasper Therapeutics, Inc. : Piper Sandler désormais positif sur le dossier	ZM

Communiqués

09/09	Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
17/08	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
14/08	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
16/07	Jasper Therapeutics Announces Merger with Kira Pharmaceuticals	AQ
01/06	Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value	AQ
14/05	Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
30/03	Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update	AQ
02/03	Jasper Therapeutics : Corporate Presentation March 2026	PU
24/02	Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference	AQ
12/01	Jasper Therapeutics : Corporate Presentation January 2026	PU
08/01	Jasper Therapeutics : Chronic Urticaria Data Update Webinar	PU
08/01	Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria	AQ
07/01	Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth	AQ
02/12	Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation	AQ
01/12	Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation	AQ
17/11	INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper	NE
16/11	Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper	NE
15/11	DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper	NE
13/11	INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper	NE
12/11	UPCOMING DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18, 2025 - JSPR	NE
11/11	Jasper Therapeutics : Corporate Presentation November 2025	PU
11/11	JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper	NE
10/11	Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
07/11	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper	NE
04/11	Jasper Therapeutics to Present at Upcoming Investor Conferences	AQ